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Antipsychotics are often used in conjunction with anti-Alzheimer drugs to treat the behavioral and
psychological symptoms of dementia (BPSD). Here, we examined the effects of cholinesterase inhibitors
(ChEIs), donepezil and galantamine, on antipsychotic-induced extrapyramidal side effects (EPS) in mice.
The effects of serotonergic agents on the EPS drug interaction were also evaluated. Donepezil (0.3e3 mg/
kg) did not induce EPS signs by itself; however, it signiﬁcantly potentiated bradykinesia induction with a
low dose of haloperidol (0.5 mg/kg) in dose-dependent and synergistic manners. Galantamine (0.3
e3 mg/kg) elicited mild bradykinesia at a high dose and dose-dependently augmented haloperidol-
induced bradykinesia. The EPS potentiation by galantamine was blocked by trihexyphenidyl (a musca-
rinic antagonist), but not by mecamylamine (a nicotinic antagonist). In addition, the bradykinesia
potentiation by galantamine was signiﬁcantly reduced by (±)-8-hydroxy-2-(di-n-propylamino)-tetralin
(a 5-HT1A agonist), ritanserin (a 5-HT2 antagonist), and SB-258585 (a 5-HT6 antagonist). The present
results give us a caution for the antipsychotics and ChEIs interaction in inducing EPS in the treatment of
BPSD. In addition, second generation antipsychotics, which can stimulate 5-HT1A receptors or antagonize
5-HT2 and 5-HT6 receptors, seem to be favorable as an adjunctive therapy for BPSD.
© 2015 The Authors. Production and hosting by Elsevier B.V. on behalf of Japanese Pharmacological
Society. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/
licenses/by-nc-nd/4.0/).1. Introduction
Alzheimer's disease is the most common neurodegenerative
disorder that shows the cognitive deﬁcits (e.g., disorientation, im-
pairments in learning and memory functions) as the primary
symptom (1). Besides cognitive deﬁcits, patients with Alzheimer's
disease often exhibit various behavioral and psycho-emotional
abnormalities, known as the behavioral and psychological symp-
toms of dementia (BPSD), including psychosis (e.g., hallucinations
and delusion), psychomotor excitement, and mood disturbances
(e.g., anxiety, depression, and the loss of motivation) (2e4). BPSD,
especially psychosis and psychomotor excitement, markedly impair
the QOL of these patients and disrupt medical treatments and
nursing care.: þ81 72 690 1053.
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d/4.0/).Since Alzheimer's disease accompanies the loss of central
acetylcholine (ACh) neurons (1,5) that control cognitive functions,
several cholinesterase inhibitors (ChEIs) such as donepezil, gal-
antamine, and rivastigmine are widely used in the treatment of
Alzheimer's disease. These agents can reverse the depletion of ACh
level in Alzheimer's disease by inhibiting cholinesterase. In addi-
tion, anti-Alzheimer's drugs are often used in combination with
antipsychotic agents which can ameliorate the BPSD (4,6,7),
yielding greater efﬁcacy over monotherapy (8). However, infor-
mation on drug interactions between antipsychotic and anti-Alz-
heimer's drugs is still limited, especially in terms of the induction of
side effects and safe combinations of these agents.
The most frequent side effects of antipsychotic drugs are
extrapyramidal motor disorders such as bradykinesia, muscle ri-
gidity, resting tremors, and akathisia (9e11). These extrapyramidal
side effects (EPS) are primarily brought about by the blockade of
striatal dopamine D2 receptors. Thus, ﬁrst generation (typical) an-
tipsychotics show high liability to induce EPS. On the other hand,
several second generation (atypical) antipsychotics with fewer EPSnese Pharmacological Society. This is an open access article under the CC BY-NC-ND
S. Shimizu et al. / Journal of Pharmacological Sciences 127 (2015) 439e445440are now available, including risperidone, perospirone, olanzapine
and quetiapine. These agents not only interact with D2 receptors,
but also with 5-HT receptors (e.g., 5-HT2, 5-HT1A and 5-HT6 re-
ceptors) (10e13) which are implicated in the atypicality of the
second generation antipsychotics (14e16). Furthermore, extrapy-
ramidal motor symptoms are also known to be controlled by the
ACh interneurons in the striatum (17).
In the present study, to evaluate the interaction between anti-
Alzheimer and antipsychotic drugs in inducing EPS, we examined
the effects of the ChEIs, donepezil and galantamine, on haloperidol-
induced bradykinesia using the mouse pole test. In addition, we
also investigated the effects of various serotonergic agents on the
antipsychotics and ChEIs interactions to clarify the possibility that
second generation antipsychotics can reduce this EPS drug
interaction.
2. Materials and methods
2.1. Animals
Male ddY mice (25e35 g) (Japan SLC, Shizuoka, Japan) were
used. Animals were housed in air-conditioned rooms under a 12-h
light/dark cycle (light on: 8:00 a.m.) and allowed ad libitum access
to food andwater. The housing conditions and animal caremethods
complied with the Guide for the Care and Use of Laboratory Ani-
mals of the Ministry of Education, Science, Sports and Culture of
Japan. The experimental protocols of this study were approved by
the Experimental Animal Research Committee at Osaka University
of Pharmaceutical Sciences.
2.2. Evaluation of bradykinesia
The pole test was performed as reported previously (18). Brieﬂy,
mice were placed head-upward at the top of a wooden pole (8 mm
in diameter and 45 cm in height), and the time for the animal to
rotate downward completely (Tturn) and descend to the ﬂoor (Ttotal)
was then measured with a cut-off time of 90 s. Animals typically
received training (3e5 min/session/day) for pole-descending
behavior for 3e4 days, and only mice that showed Tturn <8 s and
Ttotal <18 s in the pre-test trial (generally performed 2 h before the
test trial) were used.
The pole test was performed 30 min after the injection of anti-
Alzheimer drugs (i.e., donepezil and galantamine). The test doses of
donepezil and galantamine were set to those that reportedly
improved cognitive deﬁcits in rodents (19,20). In the combination
studies, haloperidol or vehicle was administered simultaneously
with the anti-Alzheimer drugs. The dose of halopeidol was set at
0.5 mg/kg (i.p.), which induced weak bradykinesia, based on the
doseeresponse of haloperidol-induced bradykinesia
(Supplemental Fig. 1). The cholinergic antagonists, trihexyphenidyl
and mecamylamine, were administered 15 min before the com-
bined treatment with galantamine (1 mg/kg, i.p.) and haloperidol
(0.5 mg/kg, i.p.).
In the experiments to examine the effects of serotonergic
agents, the 5-HT1A agonist (±)-8-hydroxy-2-(di-n-propylamino)-
tetralin ((±)-8-OH-DPAT, 0.1e1 mg/kg, i.p.), 5-HT2 antagonist
ritanserin (0.3e3 mg/kg, i.p.), 5-HT3 antagonist ondansetron
(0.1e1 mg/kg, i.p.), and 5-HT6 antagonist SB-258585 (1e10 mg/kg,
i.p.) were administered 15 min before the combined injection of
galantamine (1 mg/kg, i.p.) and haloperidol (0.5 mg/kg, i.p.). The 5-
HT1A antagonist (S)-WAY-100135 was given 15 min before the
(±)-8-OH-DPAT injection. The doses of serotonergic agents were set
to those that reversed the serotonergic (i.e., treatment of 5-
hydroxytryptophan or selective 5-HT reuptake inhibitors) poten-
tiation of EPS (21,22).2.3. Drugs
Haloperidol, donepezil hydrochloride, trihexyphenidyl hydro-
chloride, mecamylamine hydrochloride, (±)-8-OH-DPAT hydro-
bromide, ritanserin, ondansetron hydrochloride dihydrate, and SB-
258585 dihydrochloride were purchased from SigmaeAldrich (St.
Louis, MO). Galantamine hydrobromide and (S)-WAY-100135
dihydrochloride were from Tocris (Bristol, UK). Haloperidol, done-
pezil, mecamylamine, (±)-8-OH-DPAT, (S)-WAY-100135, and ritan-
serin were ﬁrst dissolved in 1% lactate solution and diluted with
physiological saline. Other agents were dissolved in physiological
saline. All drugs were injected intraperitoneally or subcutaneously
in a volume of 5 mL/kg into mice.
2.4. Statistical analysis
Data are expressed as the mean ± S.E.M. The signiﬁcance of
differences in Tturn and Ttotal values was determined by a one-way
ANOVA followed by a Tukey post hoc multiple comparisons test
(for multiple comparisons) or the Student's t-test (for two group
comparisons). When animals showed the upper limit of the obser-
vation time (90 s), comparisons were made by a non-parametric
KruskaleWallis test followed by the Steel-Dwass post hoc test (for
multiple comparisons) or ManneWhitney's U test (for two group
comparisons). A P value of less than 0.05was considered signiﬁcant.
3. Results
3.1. Effects of donepezil and galantamine on haloperidol-induced
bradykinesia
Control animals placed head-upward at the top of the pole
normally rotated downward within 3 s and descended to the ﬂoor
within 11 s (Supplemental Fig. 1).
We examined the direct effects of the ChEIs, donepezil and
galantamine, on the induction of bradykinesia. Donepezil did not
signiﬁcantly affect the pole-descending behavior of mice at doses
up to 3 mg/kg (i.p.) (Fig. 1A). Galantamine did not induce brady-
kinesia at 0.3e1 mg/kg (i.p.), but signiﬁcantly increased the pole-
descending time of mice at 3 mg/kg (Tturn: F (3,35) ¼ 8.0288,
P ¼ 0.0003, Ttotal: F (3,35) ¼ 7.3261, P ¼ 0.0006) (Fig. 1B). When co-
administered with a low dose of haloperidol (0.5 mg/kg, i.p.), which
weakly induced bradykinesia by itself (Supplemental Fig. 1),
donepezil (3 mg/kg, i.p.) and galantamine (1e3 mg/kg, i.p.) both
markedly potentiated bradykinesia induction (Tturn: X2 ¼ 13.9944,
df ¼ 3, P ¼ 0.0029 and Ttotal: X2 ¼ 15.0129, df ¼ 3, P ¼ 0.0018 for
donepezil; Tturn: X2 ¼ 22.2239, df ¼ 3, P ¼ 0.0001, Ttotal:
X2 ¼ 24.7285, df ¼ 3, P < 0.0001 for galantamine) (Fig. 1C and D).
The Ttotal value with donepezil (3 mg/kg, i.p.) or haloperidol
(0.5 mg/kg, i.p.) alone was 6.3 ± 0.89 or 14.9 ± 3.70 s, respectively
(Fig. 1A and C). However, these values increased to 62.8 ± 8.69 s
with the combined treatment using the same dose of donepezil and
haloperidol (Fig. 1C). Similarly, the Ttotal values with galantamine
(9.3 ± 0.92 and 22.2 ± 5.05 s at 1 and 3mg/kg, i.p., respectively) and
haloperidol (0.5 mg/kg, 12.4 ± 1.96 s) increased to 53.3 ± 10.51 and
59.8 ± 8.17 s, respectively, with their combination (Fig. 1B and D).
These results indicate that the potentiation of bradykinesia induc-
tion by the interaction of haloperidol and ChEIs occurred in a
synergistic manner.
We then examined the effects of trihexyphenidyl (a muscarinic
antagonist) and mecamylamine (a nicotinic antagonist) on
galantamine-enhanced bradykinesia to determine the subtype of
ACh receptors involved in the potentiation of EPS. As shown in
Fig. 1D, the induction of bradykinesia with galantamine (1 mg/kg,
i.p.) and haloperidol (0.5 mg/kg, i.p.) was completely antagonized
Fig. 1. Effects of cholinesterase inhibitors (ChEI) on haloperidol-induced bradykinesia. The pole test was performed 30 min after injections of the cholinesterase inhibitors (ChEIs)
donepezil and galantamine. In the experiments with haloperidol, it was given simultaneously with ChEI. Each column represents the mean ± S.E.M. of 6e13 mice. *P < 0.05,
**P < 0.01; Signiﬁcantly different from the control value with vehicle (A and B) or haloperidol (C and D) alone.
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(9,10) ¼ 15.0222, P ¼ 0.0002) (Fig. 2A), but was not affected by
mecamylamine (Fig. 2B).
3.2. Effects of serotonergic drugs on galantamine-enhanced
induction of bradykinesia
Since the induction of EPS is reportedly reduced by activation of
5-HT1A receptors or blockade of 5-HT2, 5-HT3, and 5-HT6 receptors
(14e16,21), we next investigated the effects of serotonergic agents
(i.e., (±)-8-OH-DPAT, ritanserin, ondansetron, and SB-258585) on
the galantamine (1 mg/kg, i.p.)-enhanced induction of bradyki-
nesia. As shown in Fig. 3A, the 5-HT1A agonist (±)-8-OH-DPAT
(0.1e1 mg/kg, i.p.) markedly attenuated galantamine and
haloperidol-induced bradykinesia in a dose-dependent manner
(Tturn: X2 ¼ 19.1601, df ¼ 3, P ¼ 0.0003, Ttotal: X2 ¼ 19.5649, df ¼ 3,P ¼ 0.0002). In particular, 0.3 and 1 mg/kg of (±)-8-OH-DPAT
reduced Tturn and Ttotal values almost to control levels (Tturn:
5.4 ± 1.29 and Ttotal: 11.7 ± 1.66 at 0.3 mg/kg, Tturn: 6.2 ± 2.55 and
Ttotal: 14.0 ± 2.79 at 1mg/kg). The ameliorative actions of (±)-8-OH-
DPAT (1 mg/kg, i.p.) on the galantamine-enhanced bradykinesia
were completely antagonized by (s)-WAY-100135 (3 mg/kg, s.c.)
(Tturn: X2 ¼ 18.2919, df ¼ 2, P ¼ 0.0001, Ttotal: X2 ¼ 18.0477, df ¼ 2,
P ¼ 0.0001) (Fig. 3B). In addition, the 5-HT2 antagonist ritanserin
(0.3e3 mg/kg, i.p.) and 5-HT6 antagonist SB-258585 (1e10 mg/kg,
i.p.) signiﬁcantly reversed galantamine-potentiated bradykinesia
(Tturn: X2 ¼ 13.3976, df ¼ 3, P ¼ 0.0039 and Ttotal: X2 ¼ 13.6573,
df ¼ 3, P ¼ 0.0034 for ritanserin; Tturn: X2 ¼ 14.6323, df ¼ 3,
P ¼ 0.0022, Ttotal: X2 ¼ 13.2154, df ¼ 3, P ¼ 0.0042 for SB258585)
(Fig. 4A and C). However, the 5-HT3 antagonist ondansetron
(0.1e1 mg/kg, i.p.) failed to signiﬁcantly affect Tturn and Ttotal values
at any dose examined (Fig. 4B).
Fig. 2. Effects of anti-cholinergic agents on the galantamine-enhanced induction of bradykinesia. The pole test was performed 30 min after a simultaneous injection of galantamine
(1 mg/kg, i.p.) and haloperidol (0.5 mg/kg, i.p.). The anti-cholinergic agents, trihexyphenidyl and mecamylamine, were given 15 min before the galantamine injection. Each column
represents the mean ± S.E.M. of 10e11 mice. **P < 0.01; Signiﬁcantly different from the control value with the injection of haloperidol and galantamine.
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Drug-induced EPS (e.g. bradykinesia, muscle rigidity, tremors,
dystonia, and akathisia) disrupt the movements and motor func-
tions of patients, which seriously impairs their QOL and daily life
activity. Speciﬁcally, antipsychotics frequently induce EPS by
blocking striatal D2 receptors (14,17). In addition, ChEIs that elevate
brain ACh levels by inhibiting cholinesterases also have the po-
tential to evoke EPS or worsen drug-induced EPS. In the present
study, we examined the effects of the ChEIs, donepezil and gal-
antamine, using doses that reportedly ameliorated cognitiveFig. 3. Effects of the 5-HT1A agonist (±)-8-OH-DPAT on the galantamine-enhanced inducti
30 min after the simultaneous injection of galantamine (1 mg/kg, i.p.) and haloperidol (0.5
injections and (s)-WAY-100135 was given 15 min before the (±)-8-OH-DPAT injection. Each
from the control value with the galantamine and haloperidol injections.deﬁcits in animals (19,20). Although these agents by themselves
were generally tolerable in inducing EPS, a high dose of galant-
amine caused mild bradykinesia. In addition, donepezil and gal-
antamine both markedly potentiated the induction of bradykinesia
when combined with a low dose of haloperidol. The potentiation of
haloperidol-induced bradykinesia by ChEIs appeared to occur in a
synergistic manner. These results give us a caution for the anti-
psychotics (D2 antagonists) and ChEIs interaction in inducing EPS in
the treatment of BPSD, even if the monotherapy with ChEIs rarely
evokes EPS. Antipsychotic-induced EPS are usually treatable with
muscarinic antagonists (e.g., trihexyphenidyl and biperiden)on of bradykinesia and its reversal by (S)-WAY-100135. The pole test was performed
mg/kg, i.p.). (±)-8-OH-DPAT was given 15 min before the haloperidol and galantamine
column represents the mean ± S.E.M. of 10e13 mice. **P < 0.01; Signiﬁcantly different
Fig. 4. Effects of 5-HT antagonists on the galantamine-enhanced induction of bradykinesia. The pole test was performed 30 min after the simultaneous injection of galantamine
(1 mg/kg, i.p.) and haloperidol (0.5 mg/kg, i.p.). 5-HT antagonists were given 15 min before the galantamine and haloperidol injections. Each column represents the mean ± S.E.M. of
8e17 mice. *P < 0.05, **P < 0.01; Signiﬁcantly different from the control value with the galantamine and haloperidol injections.
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patients with Alzheimer's disease because they impair cognitive
functions and/or counteract the therapeutic actions of ChEIs.
Therefore, information on the safety control of EPS is particularly
important in the treatment of Alzheimer's disease.
Although the precise mechanisms underlying the synergistic
potentiation of EPS by ChEIs remain unclear, they appear to involve
the D2 receptor-mediated regulation of cholinergic interneurons in
the striatum (Fig. 5). Dopamine derived from the substantia nigra
negatively regulates the ﬁring of striatal cholinergic interneurons
and the blockade of D2 receptors is known to facilitate the ﬁring ofFig. 5. A schematic diagram illustrating the striatal interaction between anti-Alzheimer an
neurons (MSNs) and acetylcholinergic interneurons receive dopaminergic inhibitory inputs
and induce extrapyramidal side effects (EPS) by blocking D2 receptors. Anti-Alzheimer drugs
cholinesterase (ChE), which leads to induction and/or worsening EPS. Particularly, ChE inhibi
in a synergistic manner. Since the blockade of D2 receptors on cholinergic interneurons fa
potently in the presence of haloperidol. In addition, stimulation of 5-HT1A receptors (located
terminals) and 5-HT6 receptors (located on acetylcholinergic interneurons) signiﬁcantly redcholinergic interneurons and enhance the ACh release (24,25).
Therefore, ChEIs may augment the induction of EPS more potently
in the presence of haloperidol (D2 antagonist) thanwith their single
administration (Fig. 5).
In this study, galantamine induced and augmented EPS more
potently than donepezil. Galantamine has been shown to have an
allosteric stimulatory effects on nicotinic ACh receptors (26,27),
which may account for higher EPS liability of this agent. However,
the potentiation of bradykinesia induction by galantamine was
completely antagonized by trihexyphenidyl, but unaffected by
macamylamine. These results strongly suggest that EPS liability byd antipsychotic drugs in induction of extrapyramidal side effects. Striatal medial spiny
from the substantia nigra pars compacta. Antipsychotics activate these striatal neurons
, donepezil and galantamine, increase the striatal acetylcholine (ACh) level by inhibiting
tors (ChEIs) markedly potentiated haloperidol (D2 antagonist)-associated EPS induction
cilitates their ﬁring and enhance the ACh release, ChEIs seem to augment EPS more
on striatal neurons) or blockade of 5-HT2 (located on dopaminergic neurons and nerve
uced EPS synergistically enhanced by haloperidol and ChEIs. DA: dopamine.
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tinic receptors are not involved. Alternatively, galantamine is
known to act as a dual inhibitor of both ACh and butylylcholine
esterases, whereas donepezil is a relatively speciﬁc inhibitor for
ACh esterase (28,29). Thus, the prominent action of galantamine
may result from its dual inhibitory actions on cholinesterases. In
addition, since donepezil, but not galantamine, reportedly has an
antagonistic effect in muscarinic receptors (30), this may also
explainwhy the EPS potentiationwith galantamine is stronger than
that with donepezil.
Extrapyramidal motor disorders are now known to be modu-
lated by multiple 5-HT receptors (11,16). The present results
showed that the galantamine-enhanced induction of bradykinesia
was markedly reduced by (±)-8-OH-DPAT. Although (±)-8-OH-
DPAT also binds to 5-HT7 receptors (31,32), the amelioration of
bradykinesia by (±)-8-OH-DPAT was completely antagonized by
the selective 5-HT1A antagonist (s)-WAY-100135, indicating that
activation of 5-HT1A receptors can reduce the bradykinesia poten-
tiation by ChEIs. We previously demonstrated that the anti-EPS
actions of 5-HT1A agonists were resistant to the presynaptic inac-
tivation of 5-HT neurons by p-chlorophenylalanine (a tryptophan
hydroxylase inhibitor), and local microinjections of (±)-8-OH-DPAT
into the cerebral cortex (i.e., motor area) or the striatum inhibited
EPS induction (18,33). Taken together, these ﬁndings indicate that
5-HT1A agonist ameliorates the potentiation of EPS by ChEIs via
their actions on postsynaptic 5-HT1A receptors, probably in the
cerebral cortex and/or striatum (Fig. 5).
In this study, ritanserin (a 5-HT2 antagonist) and SB-258585 (a
5-HT6 antagonist) reversed the galantamine-enhanced induction of
bradykinesia, indicating that the blockade of 5-HT2 and 5-HT6 re-
ceptors counteracts the potentiation of EPS by ChEIs. Our results are
consistent with the facts that blockade of 5-HT2 receptors reverses
the D2 antagonistic actions of antipsychotics (e.g., increases in ACh
release, dopamine turnover, and Fos expression) in the striatum by
relieving the 5-HT2 receptor-mediated inhibition of dopamine
neuron ﬁring in the substantia nigra and of dopamine release in the
striatum (8,10,16,23,34e37) (Fig. 5). In addition, since 5-HT6 re-
ceptors are expressed in striatal cholinergic interneurons and
mediate 5-HT-induced excitation of ACh neurons (38), 5-HT6 an-
tagonists appear to alleviate ChEIs-enhanced EPS by inhibiting the
activity of ACh neurons in the striatum (Fig. 5). On the other hand,
the 5-HT3 antagonist ondansetron negligibly affected galantamine-
potentiated bradykinesia. We previously demonstrated that the
serotonergic potentiation of EPS by 5-HT reuptake inhibitors was
reversed by a systemic treatment with, but not by an intrastriatal
microinjection of the 5-HT3 antagonist, suggesting that 5-HT3
antagonist attenuated EPS through extra-striatal mechanisms (22).
This may account for the ineffectiveness of the 5-HT3 antagonist
against the ChEIs' actions since the primary action site of ChEIs in
potentiating EPS appears to be within the striatum (cholinergic
interneurons).
5. Conclusions
Since antipsychotics are often used in conjunction with anti-
Alzheimer drugs to ameliorate psychomotor excitement of BPSD,
we evaluated the interaction between anti-Alzheimer and anti-
psychotic drugs in inducing EPS. The ChEIs, donepezil and galant-
amine, showed only marginal effects in inducing EPS by
themselves, but markedly potentiated haloperidol-induced brady-
kinesia in dose-dependent and synergistic manners. The potenti-
ation of bradykinesia by galantamine was completely blocked by
trihexyphenidyl, but not by mecamylamine, indicating the primary
involvement of muscarinic receptors in the potentiation of EPS by
ChEIs. In addition, since the stimulation of 5-HT1A receptors or theantagonism of 5-HT2 and 5-HT6 receptors effectively reversed
ChEIs-enhanced EPS, second generation antipsychotics that can
activate 5-HT1A or block 5-HT2 and 5-HT6 receptors (e.g., risperi-
done, lurasidone, olanzapine, and aripiprazole) (14,39,40) appear to
have weaker propensities to cause EPS in combined therapy with
ChEIs for the treatment of Alzheimer's disease.
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